TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Complete Remission (CR) Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: eGFR measured by MDRD formula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in energy expenditure (kcal/day)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in fat oxidation (g/min)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Mood as assessed by The Edinburgh Postnatal Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Mood as assessed by The Young Mania Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Side Effect as assessed by the Udvalg for Kliniske Undersøgelser Side Effects Rating Scale
Endpoint domain: Adverse events/effects
Primary endpoint: Side Effect as assessed by the Frequency, Intensity, and Burden of Side Effects Rating Scale
Endpoint domain: Adverse events/effects
Primary endpoint: Retinal Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative EVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of cardiovascular hospitalisations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of outpatient care visits for cardiovascular reasons
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Vaginal Superficial Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Vaginal Parabasal Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Severity of Most Bothersome Symptom (Dyspareunia)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Radiographically confirmed mechanical failure
Endpoint domain: Adverse events/effects
Primary endpoint: Modified Brice interview
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Pain Intensity Difference (PID15) At 15 Minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systolic blood pressure and diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: weight difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent Change in Radiation Dose to Healthy Human Tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression in size of the cryolesion detected by MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Lipid Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Progression (total of local, intra- and extrahepatic)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Diagnostic performance to detect advanced hepatic fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: progression of AF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean change in Level of Function (LOF) scale score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: State of the mouth and teeth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaccine-homologous Haemagglutination Inhibition (HI) Antibody Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Vaccine-homologous Microneutralization (MN) Antibody Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Geometric Increase (MGI) for Vaccine Homologous and Heterologous HI Antibody Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Geometric Increase (MGI) for Vaccine Homologous and Heterologous MN Antibody Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Left ventricle ejection fraction (LVEF) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Apixaban and Digoxin plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Headache Relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasmodium Falciparum Peripheral Parasitemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion With Composite STI Outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean Daily Composite Score Change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Total Modified PASI Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Time to third passage of confluent MSC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IDO production measured as ug/mL of passage 3 MSCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent specific inhibition of CD4 and CD8 T cell proliferation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in 24-hour urinary creatinine clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Reproducibility of CNV ERP component amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Intra-individual variability of CNV ERP component amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in cognitive performance (CNV component amplitude)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reproducibility of P300/P300' ERP component amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Intra-individual variability of P300/P300' ERP component amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Non-outpatient COPD related hospital attendance
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Bony fusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of tinnitus severity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximal tolerable dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stress (Perceived Stress Scale score)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of seizure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Duration of QTc-interval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: MTD of veliparib in combination with carboplatin and paclitaxel
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Parent Rated Social Responsiveness Scale (SRS-2) T-Score
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: amount of pain assessed using VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nature and frequency of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Flow mediated vasodilation of brachial artery measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number and Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Patients Who Experience Grade 4 or 5 Study Drug Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Radiation-induced Mucositis
Endpoint domain: Adverse events/effects
Primary endpoint: Pharmacokinetics of 111In-DOTA-hPAM4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor targeting of 111In-DOTA-hPAM4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Observed aggression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Mean Intraocular Pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aminopterin area under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Resumption of Menses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Cardiac Magnetic Resonance (CMRs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Breastfeeding Rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Vascular activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Anterior Thigh Pain Change from Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thigh Neurological Change from Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Duration of Surgery
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time-to-Discharge
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Patient Low back pain change over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long-term functional outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long-term aesthetic outcome
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in naloxone prescribing behavior
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Slope of the GFR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Disabilities of Arm, Shoulder and Hand (DASH) score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of patients who had shock reversal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in BMD from baseline in the treated knee compared to placebo
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Safety of SM04690 treatment: adverse events (AEs) and serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Propofol elimination half life
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Child mortality within the first year of life
Endpoint domain: Mortality/survival
Primary endpoint: Change in Health-related Quality of Life Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of participants with reactogenicity
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnosis power of ΔITVAo
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maximal plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Any Treatment-Emergent Adverse Events (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Fear-avoidance component scale (FACS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Disabilities of the arm, shoulder and hand questionnaire (DASH)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: White matter changes within the CNS following proton beam therapy using MRI sequences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: White matter changes within the CNS following proton beam therapy using DTI sequences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Adherence to 6-MP as measured by 6TGN and MethylTIMP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Critical level of adherence that has a significant impact on EFS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of adherence to 6-MP by ethnicity that has a significant impact on EFS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of births within 8 months of the end of the intervention
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of births before girls' 18th birthday
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of girls who sit for grade 9 exam
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Childbirth Self-Efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Delivery Expectancy/Experience
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Local treatment responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Upper limb motor functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Number of sessions attended
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Participants who are Alive at Post-transplantation Day 100
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants With Successful Engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Opiate consumption for pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Scores measured by Visual Analog Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline International Prostate Symptom Score (IPSS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with adverse events (AEs) and serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting Moderate or Greater Solicited Local Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting Moderate or Greater Solicited Systemic Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Signs of Possible Myopericarditis
Endpoint domain: Adverse events/effects
Primary endpoint: Effect on MDS-UPDRS in Parkinson's disease OFF periods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect on Physician Disease State Assessment in Parkinson's disease OFF periods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect on Patient Assessment of ON/OFF in Parkinson's disease OFF periods
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Readiness to be screened for cancer
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Physician-patient discussions about PSA screening
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rates of cancer screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Grade 3+ Treatment-related Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric mean titre (GMT) consistency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and severity of adverse reactions/adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Pain relief within 3 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of ventilator-free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cervical motions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily average postoperative pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative functional recovery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of confirmed Herpes Zoster (HZ) cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Study participation rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Upper Extremite Fugl-Meyer Assessment (UA-FMA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative skin pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Detection of EC-specific methylation markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Transition Readiness Score Overall
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time Between Onset of Apnea and the Drop in 95% Oxyhemoglobin Saturation Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Radiation exposure of the operator
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exclusive breastfeeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: Change From Baseline in Trough Forced Expiratory Volume in 1 Second
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Immune competence against CMV infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in HIV risk behavior
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Receipt of opportunistic infection (OI) prophylaxis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Adherence to antiretroviral therapy (ART)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change on Brief Symptom Inventory - short form (BSI-18)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Capacity to maintain therapeutic success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients Achieving Glycosylated Hemoglobin A1c (HbA1c) < 7.0%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Kinematics (joint range of motion)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electromyography(EMG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle Strength Assessment by Dynamometer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kinetic(Ground reaction force)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transcranial magnetic stimulation (TMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of Number of Alerts Generated by Symptom Distress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensorimotor brain activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sustained Virologic Response at Follow-up Week 12 (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Perceptual evaluation of low back pain
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in Beck Scale for Suicide Ideation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: success rate of the Predictix tool
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from Baseline in Chest Radiography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Helpfulness of informational leaflets
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fugl-Meyer Upper Extremity Motor Assessment (FMUE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chedoke McMaster Stroke Assessment Stage of Hand (CMSA-H)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease-free/Relapse-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants With Psoriasis Area Sensitivity Index 75 (PASI-75) Response at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Experiencing an Adverse Event Up to Week 12
Endpoint domain: Adverse events/effects
Primary endpoint: Post-operative Pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incident of oral Morbidities related to the procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Unified Parkinson's Disease Rating Scale (UPDRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional axial rotation - physical (FAR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gait and turning characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Growth of children with cerebral palsy who have chewing disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Persistant organic pollutants dosage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in photosensitivity response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes